

20 Jun 2021 |

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Scrip's Five Must-Know Things: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm's plans for lung disease leadership.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 June 2021, including: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm's plans for lung leadership.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone](#)" - Scrip, 14 Jun, 2021.)

(Also see "[Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm](#)" - Scrip, 12 Jun, 2021.)

(Also see "[Does New Study Question Need for Pediatric COVID-19 Vaccines?](#)" - Scrip, 14 Jun, 2021.)

(Also see "[ASCO Data Position Contenders In Battle Of The SERDs](#)" - Scrip, 14 Jun, 2021.)

(Also see "[How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans](#)" - Scrip, 14 Jun,

2021.)

[Click here to explore this interactive content online](#) 